Aravive To Present at The 2020 RBC Capital Markets Global Healthcare Conference
12 mai 2020 08h00 HE
|
Aravive, Inc.
HOUSTON, May 12, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates
06 mai 2020 16h05 HE
|
Aravive, Inc.
HOUSTON, May 06, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
30 avr. 2020 08h00 HE
|
Aravive, Inc.
HOUSTON and SHANGHAI, April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with...
Aravive Announces Board Composition and Executive Management Transitions
09 avr. 2020 07h08 HE
|
Aravive, Inc.
Healthcare Entrepreneur Fred Eshelman, Pharm.D., Appointed Board Chairman Aravive’s Chief Scientific Officer, Gail McIntyre, Ph.D., Appointed CEO Aravive to Host Conference Call Today at 9:00 AM ET ...
Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
30 mars 2020 08h00 HE
|
Aravive, Inc.
Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of...
Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates
27 mars 2020 08h00 HE
|
Aravive, Inc.
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020Company announces clinical trial updates for clear cell...
Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
24 mars 2020 08h00 HE
|
Aravive, Inc.
HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored...
Aravive To Present at The Cowen and Company 40th Annual Health Care Conference
25 févr. 2020 16h07 HE
|
Aravive, Inc.
HOUSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will present at Cowen and Company's 40th Annual Health...
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
18 févr. 2020 08h00 HE
|
Aravive, Inc.
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by...
Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
13 janv. 2020 08h00 HE
|
Aravive, Inc.
HOUSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the...